{
    "clinical_study": {
        "@rank": "144499", 
        "arm_group": [
            {
                "arm_group_label": "recombinant hepatitis b vaccine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.5ml intramuscular"
            }, 
            {
                "arm_group_label": "Aleph influenza vaccine", 
                "arm_group_type": "Experimental", 
                "description": "0.5ml intramuscular"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to evaluate the safety and immunogenicity of one inactivated\n      split influenza vaccine, a primarily Chinese-marketed trivalent vaccine."
        }, 
        "brief_title": "Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "A total of 3308 subjects were stratified equally into four age groups and receive either\n      influenza vaccine or recombinant hepatitis b vaccine (seen as placebo). Systematic and local\n      adverse reactions were reported for 28 d after the vaccination. Antibody levels were\n      detected through hemagglutination inhibition assay before vaccination (Baseline) and 28d\n      after the vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  more than three years in good healthy\n\n        Exclusion Criteria:\n\n          -  current infectious fever or acute disease\n\n          -  upper respiratory infectious symptom within 6m\n\n          -  a history of allergy\n\n          -  laboratory confirmed influenza\n\n          -  autoimmune disease\n\n          -  have get influenza vaccine since 2008"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "3308", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758185", 
            "org_study_id": "BJCDPC-3"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "recombinant hepatitis b vaccine", 
                    "Aleph influenza vaccine"
                ], 
                "description": "0.5ml intramuscular", 
                "intervention_name": "recombinant hepatitis b vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "recombinant hepatitis b vaccine", 
                    "Aleph influenza vaccine"
                ], 
                "description": "0.5ml intramuscular", 
                "intervention_name": "Aleph influenza vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Inactivated split influenza vaccine", 
            "Immunogenicity", 
            "Safety", 
            "Consistence"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zhangjiakou", 
                        "country": "China", 
                        "state": "Hebei"
                    }, 
                    "name": "Zhuolu County Center for Disease Control and Prevention"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zhangjiakou", 
                        "country": "China", 
                        "state": "Hebei"
                    }, 
                    "name": "Xinglong County Center for Disease Control and Prevention"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine", 
        "overall_official": {
            "affiliation": "Beijing Chaoyang District Center for Disease Control and Prevention", 
            "last_name": "Nianmin Shi, Master", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence rate of adverse events of the inactivated split influenza vaccine", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758185"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Antibody titre of the inactivated split influenza vaccine", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "source": "Beijing Center for Disease Control and Prevention", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}